» Articles » PMID: 23180981

The Role of Exposure History on HIV Acquisition: Insights from Repeated Low-dose Challenge Studies

Overview
Specialty Biology
Date 2012 Nov 28
PMID 23180981
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

To assess the efficacy of HIV vaccine candidates or preventive treatment, many research groups have started to challenge monkeys repeatedly with low doses of the virus. Such challenge data provide a unique opportunity to assess the importance of exposure history for the acquisition of the infection. I developed stochastic models to analyze previously published challenge data. In the mathematical models, I allowed for variation of the animals' susceptibility to infection across challenge repeats, or across animals. In none of the studies I analyzed, I found evidence for an immunizing effect of non-infecting challenges, and in most studies, there is no evidence for variation in the susceptibilities to the challenges across animals. A notable exception was a challenge experiment by Letvin et al. Sci Translat Med (2011) conducted with the strain SIVsmE660. The challenge data of this experiment showed significant susceptibility variation from animal-to-animal, which is consistent with previously established genetic differences between the involved animals. For the studies which did not show significant immunizing effects and susceptibility differences, I conducted a power analysis and could thus exclude a very strong immunization effect for some of the studies. These findings validate the assumption that non-infecting challenges do not immunize an animal - an assumption that is central in the argument that repeated low-dose challenge experiments increase the statistical power of preclinical HIV vaccine trials. They are also relevant for our understanding of the role of exposure history for HIV acquisition and forecasting the epidemiological spread of HIV.

Citing Articles

Dose-dependent interaction of parasites with tiers of host defense predicts "wormholes" that prolong infection at intermediate inoculum sizes.

Graham A, Regoes R PLoS Comput Biol. 2024; 20(12):e1012652.

PMID: 39642189 PMC: 11654943. DOI: 10.1371/journal.pcbi.1012652.


Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models.

Khoury D, Wheatley A, Ramuta M, Reynaldi A, Cromer D, Subbarao K Nat Rev Immunol. 2020; 20(12):727-738.

PMID: 33139888 PMC: 7605490. DOI: 10.1038/s41577-020-00471-1.


Comparative Evaluation of Prophylactic SIV Vaccination Modalities Administered to the Oral Cavity.

Chaudhary O, Wang L, Bose D, Narayan V, Yeh M, Carville A AIDS Res Hum Retroviruses. 2020; 36(12):984-997.

PMID: 32962398 PMC: 7703093. DOI: 10.1089/AID.2020.0157.


Disentangling non-specific and specific transgenerational immune priming components in host-parasite interactions.

Ben-Ami F, Orlic C, Regoes R Proc Biol Sci. 2020; 287(1920):20192386.

PMID: 32075526 PMC: 7031663. DOI: 10.1098/rspb.2019.2386.


Early HIV infection predictions: role of viral replication errors.

Conway J, Perelson A SIAM J Appl Math. 2019; 78(4):1863-1890.

PMID: 31231142 PMC: 6588189. DOI: 10.1137/17M1134019.


References
1.
Hansen S, Vieville C, Whizin N, Coyne-Johnson L, Siess D, Drummond D . Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009; 15(3):293-9. PMC: 2720091. DOI: 10.1038/nm.1935. View

2.
Ellenberger D, Otten R, Li B, Aidoo M, Rodriguez I, Sariol C . HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology. 2006; 352(1):216-25. DOI: 10.1016/j.virol.2006.04.005. View

3.
Regoes R, Longini I, Feinberg M, Staprans S . Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med. 2005; 2(8):e249. PMC: 1176242. DOI: 10.1371/journal.pmed.0020249. View

4.
Otten R, Adams D, Kim C, Jackson E, Pullium J, Lee K . Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis. 2004; 191(2):164-73. DOI: 10.1086/426452. View

5.
Van Rompay K, Abel K, Lawson J, Singh R, Schmidt K, Evans T . Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr. 2005; 38(2):124-34. DOI: 10.1097/00126334-200502010-00002. View